5-FU improves p27-related poor prognosis in patients with Astler-Coller B2-C colorectal carcinoma

Oncology Reports

Volumn 9, Issue 1, 2002, Pages 29-33

  Kobayashi, Minako ^a   Shiraishi, Taizo ^a   Tonouchi, Hitoshi ^a   Miki, Chikao ^a   Kusunoki, Masato ^a  

^a MIE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

5 FU; Colorectal cancer; P27kip1

Indexed keywords

1 UFT PROTOCOL; 1-UFT PROTOCOL; ANTINEOPLASTIC AGENT; CDKN1B; CELL CYCLE PROTEIN; FLUOROURACIL; TEGAFUR; TUMOR SUPPRESSOR PROTEIN; URACIL;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CANCER INVASION; CANCER STAGING; COLORECTAL TUMOR; ENZYME IMMUNOASSAY; FEMALE; HUMAN; LYMPH NODE METASTASIS; MALE; METABOLISM; MORTALITY; PROGNOSIS; SURVIVAL RATE;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL CYCLE PROTEINS; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMAN; IMMUNOENZYME TECHNIQUES; LYMPHATIC METASTASIS; MALE; MIDDLE AGE; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE; TEGAFUR; TUMOR SUPPRESSOR PROTEINS; URACIL;

EID: 0036134342     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.9.1.29     Document Type: Article

References (29)

1. Poylak K, Lee MH, Erdjument-Bromage A, Roberts JM, Tempst P and Massague J: Cloning of p27kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 78: 59-66, 1994.
2. Iniesta P, Vega FJ, Caldes T, Massa M, De Juan C, Cerdan FJ, Sanchez A, Lopez JA, Torres AJ, Balibrea JL and Benito M: p53 exon 7 mutations as predictor of poor prognosis in patients with colorectal cancer. Cancer Lett 14: 153-160, 1998. (Pubitemid 28425349)
3. Nakayama K, Ishida N, Shirane M, Inomata A, Inoue T, Shishidu N, Horii I, et al: Mice lacking p27kip1 display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 85: 707-720, 1996.
4. Deng C, Zhang P, Harper JW, Elledge SJ and Leder P: Mice lacking p21waf1/cip1 undergo normal development but are defective in G1 checkpoint control. Cell 82: 675-684, 1995.
5. Catzavelos C, Bhattacharya N, Ung YC, et al: Decreased levels of the cell-cycle inhibitor p27kip1 protein: prognostic implications in primary breast cancer. Nat Med 3: 227-230, 1997. (Pubitemid 27064710)
6. Esposito V, Baldi A, De Luca A, et al: Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res 57: 3381-3385, 1997. (Pubitemid 27355479)
7. Mori M, Mimori K, Shiraishi T, et al: P27 expression and gastric carcinoma. Nat Med 3: 593, 1997.
8. Palmqvist R, Stenling R, Oberg A and Landberg G: Prognostic significance of p27kip1 expression in colorectal cancer: a clinico-pathological characterization. J Pathol 188: 18-23, 1999. (Pubitemid 29197309)
9. Guther K, Jung A, Volker U, et al: P27kip1 expression in rectal cancer correlates with disease-free survival. J Surg Res 92: 78-84, 2000. (Pubitemid 30437463)
10. Fujii S, Fukushima M, Shimamoto Y and Shirasaki T: Pharmacokinetic modulation of plasma 5-fluorouracil concentration to potentiate the antitumor activity of continuous venous infusion of 5-fluorouracil. Jpn J Cancer Res 80: 509-512, 1989. (Pubitemid 20032476)
11. Toyoshima H and Hunter T: p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell 78: 67-74, 1994. (Pubitemid 24228301)
12. Katt J-Y, Matsuoka M, Polyak K, Massague J and Sherr CJ: Cyclic AMP-induced G1 phase arrest mediated by inhibitor (p27kip1) of cyclin-dependent kinase 4 activation. Cell 79: 487-496, 1994.
13. Nourse J, Firpo E, Flanagen MW, Coats S, Polyak K, Lee M-H, Massague J, Crabtree GR and Roberts JM: Interleukin-2-mediated elimination of the p27kip1 cyclin-dependent kinase inhibitor prevented by rapamycin. Nature 372: 570-573, 1994.
14. Harvat LV, Seth P and Jatten AM: The role of p27kip1 in gamma interferon-mediated growth arrest of mammary epithelial cell and related defects in mammary carcinoma cell. Oncogene 372: 570-573, 1997.
15. Kuniyasu H, Yasui W, Kitahara K, Naka K, Yokozaki H, Akama Y, Hamamoto T, et al: Growth inhibitory effect of interferon-beta is associated with the induction of cyclin dependent kinase inhibitor p27kip1 in a human gastric cell line. Cell Growth Differ 8: 47-52, 1997. (Pubitemid 27030237)
16. Rivard N, L'Alleimain G, Bartek J and Pouyssegur J: Abrogation of p27kip1 by cDNA antisense suppresses quiescence (G0 state) in fibroblasts. J Biol Chem 271: 18337-18341, 1996. (Pubitemid 26322686)
17. Kranenburg O, Scharnhorst V, van der Eb A and Zantema A: Inhibition of blastoma cells. J Cell Biol 131: 227-234, 1995.
18. Hengst L and Reed SI: Translational control of p27kip1 accumulation during the cell cycle. Science 217: 1861-1864, 1996.
19. Pagano M, Draetta GF and Rolfe M: Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 269: 682-685, 1995.
20. Hong Z and Xiao F: Loss of p27 expression predicts poor prognosis in patients with Dukes' B stage or proximal colorectal cancer. Int J Oncol 19: 49-52, 2001.
21. Pietenpol JA, Bohlander SK, Sato Y, Papadopoulos N, Liu B, Friedman C, Trask BJ, Roberts JM, Kinzler KW, Rowley JD and Vogelstein B: Assignment of the human p27kip1 gene to 12p13 and its analysis in leukemias. Cancer Res 55: 1206-1210, 1995.
22. Bullrich F, MacLachlan TK, Sang N, Druck T, Veronese ML, Allen SL, Chiorazzi N, Koff A, Heubner K, Croce CM and Giordano A: Chromosomal mapping of members of the cdc2 family of protein kinases, cdk3, cdk6, PISSLRE, and PITALRE, and a cdk inhibitor, p27kip1, to regions involved in human cancer. Cancer Res 55: 1199-1205, 1995.
23. Ponce-Castaneda MV, Lee M-H, Latres E, Polyak K, Lacombe L, Montgomery K, Mathew S, Krauter K, Sheinfeld J, Massague J and Cordon-Cardo C: p27kip1: chromosomal mapping to 12p12-12p13.1 and absence of mutation in human tumors. Cancer Res 55: 1211-1214, 1995.
24. Loda M, Cukor B, Tam SW, et al: Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med 3: 231-234, 1997. (Pubitemid 27064711)
25. Porter PL, Malone KE, Heagerty PJ, et al: Expression of cell-cycle regulators p27kip1 and cyclin E, alone and in combination, correlates with survival in young breast cancer patients. Nat Med 3: 222-225, 1997. (Pubitemid 27064709)
26. Yung RM, Naitoh J, Murphy M, et al: Low expression predicts poor disease-free survival in patients with prostate cancer. J Urol 159: 941-945, 1998. (Pubitemid 28106561)
27. Kusunoki M, Yanagi H, Noda M and Yamamura T: The usefulness of pharmacokinetic modulating chemotherapy (UFT plus 5-FU) in the treatment of unresectable colorectal carcinomas. Oncol Rep 6: 547-552, 1999.
28. Yoshikawa R, Kusunoki M, Yanagi H, Noda M, Furuyama J and Yamamura T: Dual anti-tumor effects of 5-fluorouracil (5-FU) on the cell cycle in colorectal carcinoma cell; a novel target mechanism concept for pharmacokinetic modulating chemotherapy. Cancer Res 61: 1029-1037, 2001. (Pubitemid 32174421)
29. Kusunoki M, Yanagi H, Noda M, Yoshikawa R and Yamamura T: Results of pharmacokinetic modulation chemotherapy in combination with hepatic arterial 5-fluorouracil hepatic colorectal metastases. Cancer 89: 1228-1235, 2000.